<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822376</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 0006S</org_study_id>
    <nct_id>NCT04822376</nct_id>
  </id_info>
  <brief_title>Prophylaxis Vaccine Antibodies Ebola</brief_title>
  <acronym>PROVAE</acronym>
  <official_title>Phase IIa Pilot Study Evaluating the Efficacy of a Monoclonal Antibody and Vaccine-based Post-exposure Prophylaxis Strategy in High-risk Contact Cases of Ebola Virus Disease Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Three measures are currently being implemented to control Ebola outbreaks:&#xD;
&#xD;
             -  Monitoring of contacts&#xD;
&#xD;
             -  Isolation and treatment of sick people&#xD;
&#xD;
             -  Vaccination of the population in high-risk areas.&#xD;
&#xD;
        -  In contacts with high viral exposure and therefore a high risk of incubation and rapid&#xD;
           expression of infection, the r-VSV-ZEBOV vaccine does not provide adequate protection&#xD;
           because vaccine antibody production is effective 6 to 10 days after administration.&#xD;
&#xD;
        -  Specific monoclonal antibodies (Mab) from the Regeneron and mAb114 research specialties&#xD;
           have been shown to be effective in reducing mortality in patients with Ebola virus&#xD;
           disease (EVD).&#xD;
&#xD;
        -  Their use in a single parenteral administration and good tolerability make them&#xD;
           candidates for use in post-exposure prophylaxis (PEP) in individuals at high risk of&#xD;
           viral exposure.&#xD;
&#xD;
        -  A comprehensive strategy for the protection of high-risk contacts must therefore be&#xD;
           implemented, including the vaccine and the Mabs, to ensure both immediate and prolonged&#xD;
           protection. Indeed, the efficacy of the vaccine is likely to be diminished when&#xD;
           co-administered with Mabs, as both strategies share the same viral target (the GP&#xD;
           envelope glycoprotein) and the vaccine is replicative (and therefore may be inhibited by&#xD;
           Mabs).&#xD;
&#xD;
      PROVAE aim to evaluate the effectiveness of a comprehensive strategy to prevent transmission&#xD;
      of MVE in contacts at high risk of infection, including (i) post-exposure prophylaxis with&#xD;
      Mabs and (ii) vaccination with r-VSV-ZEBOV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 17, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Efficacy trial : Exploratory, non-comparative, unblinded trial with Mab at D0 and vaccine at W6.&#xD;
Immunological ancillary study : Exploratory, controlled, comparative, non-randomized, 2-group, unblinded study comparing Mab at D0 and vaccine at W6 for high-risk contacts with vaccine at D0 for vaccinated contacts.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Week 3</time_frame>
    <description>Proportion of participants with negative RT-PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological ancillary study</measure>
    <time_frame>6 months after vaccination</time_frame>
    <description>Anti-GP IgG level (FANG reference technique)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
    <time_frame>Day 7 post-PEP and day 7 post-vaccination</time_frame>
    <description>Estimating adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lost of follow-up</measure>
    <time_frame>Week 6</time_frame>
    <description>Lost of follow-up rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Humoral immune response</measure>
    <time_frame>1 and 3 months after vaccination</time_frame>
    <description>Anti-GP IgG level (FANG reference technique)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies</measure>
    <time_frame>1, 3 and 6 months after vaccination</time_frame>
    <description>Neutralizing antibodies level</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Ebola Virus Disease</condition>
  <arm_group>
    <arm_group_label>High risk arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mabs at day 0 and vaccine at week 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk arm (Immunological ancillary study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mabs at day 0 and vaccine at week 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm (Immunological ancillary study)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine at day 0 for contacts eligible for vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ansuvimab</intervention_name>
    <description>Human monoclonal antibody to Zaire strain GP (EBOV GP)</description>
    <arm_group_label>High risk arm</arm_group_label>
    <arm_group_label>High risk arm (Immunological ancillary study)</arm_group_label>
    <other_name>mab114</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ervebo</intervention_name>
    <description>Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)</description>
    <arm_group_label>Control arm (Immunological ancillary study)</arm_group_label>
    <arm_group_label>High risk arm</arm_group_label>
    <arm_group_label>High risk arm (Immunological ancillary study)</arm_group_label>
    <other_name>VSV-ZEBOV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The inclusion criteria for the efficacy trial are:&#xD;
&#xD;
          -  Have had, within the previous 72 hours, a high-risk contact with an Ebola patient&#xD;
             confirmed by RT-PCR;&#xD;
&#xD;
          -  Be 18 years of age or older at the time of inclusion;&#xD;
&#xD;
          -  Have no symptoms of EVD;&#xD;
&#xD;
          -  Give consent to participate in the efficacy trial;&#xD;
&#xD;
          -  Agree not to participate in any other therapeutic or vaccine study until the end of&#xD;
             the trial follow-up.&#xD;
&#xD;
        The criteria for non-inclusion in the efficacy trial are:&#xD;
&#xD;
          -  Have a history of EVD (self-report);&#xD;
&#xD;
          -  Have been vaccinated with ERVEBO prior to the start of the study;&#xD;
&#xD;
          -  Have participated in another therapeutic or vaccine study within 15 days prior to&#xD;
             inclusion.&#xD;
&#xD;
        Inclusion criteria for the immunology ancillary study are:&#xD;
&#xD;
        High Risk Arm:&#xD;
&#xD;
          -  Be included in the efficacy trial;&#xD;
&#xD;
          -  Be available for extended follow-up as specified in the protocol;&#xD;
&#xD;
          -  Specifically consent to the immunology ancillary study.&#xD;
&#xD;
        Control arm:&#xD;
&#xD;
          -  Be 18 years of age or older at the time of inclusion;&#xD;
&#xD;
          -  Have no symptoms of EVD;&#xD;
&#xD;
          -  Eligible for ERVEBO vaccination according to national program criteria;&#xD;
&#xD;
          -  Be available for extended follow-up as specified in the protocol;&#xD;
&#xD;
          -  Consent specifically for the ancillary immunology study.&#xD;
&#xD;
        The criteria for non-inclusion in the immunologic ancillary study are:&#xD;
&#xD;
          -  All efficacy trial non-inclusion criteria;&#xD;
&#xD;
          -  HIV positive;&#xD;
&#xD;
          -  Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie Jaspard, MD</last_name>
    <email>marie.jaspard@coral.alima.ngo</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Traitement Ebola de N'Zerekore</name>
      <address>
        <city>N'Zerekore</city>
        <country>Guinea</country>
      </address>
    </facility>
    <contact>
      <last_name>Sakoba Keita, MD</last_name>
      <phone>+224 624510581</phone>
      <email>sakoba54@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Guinea</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

